London, Ontario (May 20, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) - today announced positive
results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the
CHEMSAS(R) drug discovery technology.
The significance of these results is that the majority of currently marketed and developmental stage HIV Integrase inhibitors have a very similar way
of interacting with and inhibiting the enzyme through a diketo acid type moiety. COTI has used its proprietary technology, CHEMSAS(R), to discover several novel small
molecule scaffolds that have an entirely new binding mode and interaction with the active site of the viral enzyme.
COTI has completed the synthesis and initial confirmatory in vitro testing of the first three novel scaffolds from this program. All three scaffolds
demonstrated good inhibitory activity in a biochemical HIV integrase assay at nanomolar concentrations. On the basis of these results, COTI has filed composition of matter
patents and intends to proceed with the next phase of this project that consists of optimizing a small series of potential lead candidates based on these scaffolds.
"These encouraging results provide further validation of our CHEMSAS(R) technology and its ability to rapidly identify innovative small molecules
for difficult drug targets. The discovery of new HIV integrase inhibiting scaffolds having an entirely novel mode of interacting with the enzyme has been challenging for HIV
researchers, which makes these early results quite gratifying," said Dr Wayne Danter, COTI's President and CSO.
As previously announced, these novel scaffolds are part of a co-development program with a major pharmaceutical partner. The co-development partner is now conducting and
funding agreed upon in vitro experiments in their evaluation of the compounds. Once these experiments have been completed and the results have been received by COTI, the
co-development partner will have an exclusive time period to negotiate a licensing agreement with COTI for the compounds.
Notice to Readers
Information contained in this press release may contain certain statements which constitute "forward- looking statements" within the meaning of the Securities Act (Ontario)
and applicable securities laws. For example, the statement "intends to proceed with the next phase of this project" is a forward-looking statement. Forward-looking statements,
by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a
highly competitive environment that involves significant risks and uncertainties which could cause actual results to differ materially from those anticipated in these
forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of
the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements.
Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information
disclosed in later press releases, filings with the securities regulatory authorities or otherwise.
About HIV
According to the UNAIDS 2008 Report on the Global AIDS Epidemic, there are 33 million people living with HIV around the globe. The annual number of new infections is approximately 2.7 million
worldwide. In 2008, the HIV market was worth $11 billion across the seven major markets of France, Germany, Italy, Japan, Spain, the UK and the US and it is expected to grow to $16 billion
by 2018. This growth is driven by the growing prevalence of HIV worldwide as well as the increasing life expectancy of those receiving treatment.
About Integrase Inhibitors
The development of HIV integrase inhibitors marks an important frontier in HIV research as integrase is one of the only enzymes that researchers have had difficulty targeting. Data from
large efficacy trials suggests that drug combinations containing an integrase inhibitor achieved substantial levels of viral suppression in patients with drug-resistant HIV. The response
seen in patients was equivalent to that seen when highly active antiretroviral therapy became available.
About Critical Outcome Technologies Inc. (COTI)
COTI is formed around a unique computational platform technology called CHEMSAS(R), which allows for accelerated identification and optimization of targeted small molecules potentially
effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI is focused on preparing its lead anti cancer compound, COTI-2, for an
Investigational New Drug filing in the USA in 2011. In addition to COTI-2, the company has a significant preclinical pipeline targeting large market opportunities such as: small
cell lung and colorectal cancer, adult acute leukemia and other cancers, multiple sclerosis, HIV integrase, and Alzheimer's disease. For further information,
visit www.criticaloutcome.com.
###
CONTACT:
Critical Outcome Technologies Inc. (COTI)
Michael Barr
Director of Business Development and Marketing
519-858-5157
mbarr@criticaloutcome.com
www.criticaloutcome.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.
"Reproduced with permission - Critical Outcome Technologies Inc. (COTI)"
Critical Outcome Technologies Inc. (COTI)
|
